These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Glycoprotein IIb/IIIa inhibitors: an update on the mechanism of action and use of functional testing methods to assess antiplatelet efficacy. Lippi G; Montagnana M; Danese E; Favaloro EJ; Franchini M Biomark Med; 2011 Feb; 5(1):63-70. PubMed ID: 21319966 [TBL] [Abstract][Full Text] [Related]
63. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Chew DP; Bhatt DL; Sapp S; Topol EJ Circulation; 2001 Jan; 103(2):201-6. PubMed ID: 11208677 [TBL] [Abstract][Full Text] [Related]
64. Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease. Berkowitz SD Haemostasis; 2000; 30 Suppl 3():27-43. PubMed ID: 11182626 [TBL] [Abstract][Full Text] [Related]
65. Efficacy and safety of glycoprotein IIb/IIIa receptor antagonists for patients undergoing percutaneous coronary intervention within twelve hours of fibrinolysis. Belle L; Fourny M; Reynaud T; Hammer L; Vanzetto G; Labarère J; Catheter Cardiovasc Interv; 2011 Sep; 78(3):376-84. PubMed ID: 21413113 [TBL] [Abstract][Full Text] [Related]
66. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Adgey AA Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518 [TBL] [Abstract][Full Text] [Related]
67. Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors. Kleiman NS Am Heart J; 1999 Oct; 138(4 Pt 2):263-75. PubMed ID: 10502232 [TBL] [Abstract][Full Text] [Related]
68. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. Montalescot G; Borentain M; Payot L; Collet JP; Thomas D JAMA; 2004 Jul; 292(3):362-6. PubMed ID: 15265852 [TBL] [Abstract][Full Text] [Related]
69. The role of platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary revascularization procedures. Dangas G; Fuster V Rev Port Cardiol; 1999 Feb; 18 Suppl 1():I49-53. PubMed ID: 10191675 [TBL] [Abstract][Full Text] [Related]
75. Platelet glycoprotein IIb/IIIa polymorphism and coronary artery disease: implications for clinical practice. Di Castelnuovo A; de Gaetano G; Benedetta Donati M; Iacoviello L Am J Pharmacogenomics; 2005; 5(2):93-9. PubMed ID: 15813672 [TBL] [Abstract][Full Text] [Related]
76. Small-molecule glycoprotein IIb/IIIa inhibitors as adjunctive therapy in percutaneous coronary interventions. O'Shea JC; Tcheng JE J Thromb Thrombolysis; 2000 Dec; 10(3):211-5. PubMed ID: 11122539 [No Abstract] [Full Text] [Related]
77. Platelet glycoprotein IIb/IIIa antagonists in clinical trials for the treatment of coronary artery disease. Salam AM; Suwaidi JA Expert Opin Investig Drugs; 2002 Nov; 11(11):1645-58. PubMed ID: 12437510 [TBL] [Abstract][Full Text] [Related]
78. Synthesis and pharmacology of modified amidine isoxazoline glycoprotein IIb/IIIa receptor antagonists. Sielecki TM; Liu J; Mousa SA; Racanelli AL; Hausner EA; Wexler RR; Olson RE Bioorg Med Chem Lett; 2001 Aug; 11(16):2201-4. PubMed ID: 11514170 [TBL] [Abstract][Full Text] [Related]
79. Antiplatelet therapies: from aspirin to GPIIb/IIIa-receptor antagonists and beyond. Mousa SA Drug Discov Today; 1999 Dec; 4(12):552-561. PubMed ID: 10557137 [TBL] [Abstract][Full Text] [Related]
80. New drugs: fenoldopam mesylate, glycoprotein IIb/IIIa antagonists, and K+ATP-channel agonists. Vijayakumar E Int Anesthesiol Clin; 2002; 40(1):35-60. PubMed ID: 11910249 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]